Profile
Our lab is focused on the application of mass spectrometry-based quantitative proteomics approaches to identify biomarkers and therapeutic targets in a number of cancers including breast cancer and haematological malignancies. We are using state-of-the-art mass spectrometric quantitative methods to identify differentially regulated proteins between non-neoplastic and neoplastic conditions and for characterizing post-translational modifications for several cancers. Candidate target markers are validated using immuno assays as well as SRM assays. Further potential biomarkers are subjected for functional studies to understand the mechanistic insights using molecular biology tools. In addition, our lab is also focused on identifying and quantifying key metabolites and lipids associated with various cancers using mass spectrometry and bioinformatics. The results of integrated proteomics and metabolomics data can be used to identify biochemical pathways involved in particular cancer and eventually for the identification of new prognostic and predictive biomarkers.
Current Focus Areas
Combining proteomics and metabolomic approaches with molecular approaches to gain deeper insights into underlying mechanisms and pathways of various cancers including breast cancer, multiple myeloma and leukemias.
Selected Publications
1. Chanukuppa V, Taware R, Taunk K, Chatterjee T, Sharma S, Somasundaram V, Rashid F, Malakar D, Santra MK, Rapole S. (2021) Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples. Frontiers in Oncology 10:566804. 2. Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Shirolkar A, Islam S, Santra MK, Rapole S. (2020) Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma. International Journal of Oncology 57:325-337. 3. More TH, RoyChoudhury S, Christie J, Taunk K, Mane A, Santra MK, Chaudhury K, Rapole S. (2018) Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples. Oncotarget 9: 2678-2696. 4. Gajbhiye A, Dabhi R, Taunk K, Jagadheeshaprasad MG, RoyChoudhury S, Mane A, Bayatigeri S, Chaudhury K, Santra MK, Rapole S. (2017) Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes. Journal of Proteomics 163: 1-13. 5. Gajbhiye A, Dabhi R, Taunk K, Vannuruswamy G, RoyChoudhury S, Adhav R, Seal S, Mane A, Bayatigeri S, Santra MK, Chaudhury K, Rapole S. (2016) Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics. Proteomics 16: 2403-18.